The exciting progression of PROTAC-based therapies and other degrader modalities continues to redefine the therapeutic landscape among the biopharmaceutical industry. As the quest to ‘drug the undruggable’ with targeted protein degradation heats up, challenges still remain to advance orally bioavailable candidates towards the clinic.
The Targeted Protein Degradation Europe Summit provides you with a platform of learning, discovery, and networking opportunity to hear the latest developments and advancements from the leaders of the protein degradation field to maximise the therapeutic window of your TPD strategies.
Bringing together the leading biopharmaceutical and academic organisations from the European scene in an intimate digital environment, TPD Europe focuses on successfully discovering novel E3 ligases & optimising drug-like properties to harness the full therapeutic opportunity of orally bioavailable protein degraders in oncology & beyond.
With the goal of accelerating the translation of selective, bioavailable and effective protein degraders towards clinical trials, join 100+ pioneers, leaders and enthusiasts to capitalise on this emerging therapeutic class and make targeted protein degradation a blockbuster therapeutic approach that improves patient outcomes.